Another dimension of the war on cancer that we all just sort of side step is the cost associated with scientific advances and age-cohort driven cancer care. How are we to pay for all this great care. Payors (Medicare and commercial health plans) are working feverishly to reduce their cancer "medical cost" inflation by moving to more restrictive pharmacy benefit management and pre-treatment medical management approval processes. So, on the one hand, we are excited about funding breakthrough research, yet we appear disinterested/distracted when it comes to the question of who is going to pay for it all.









Discuss